Napredna pretraga

Pregled bibliografske jedinice broj: 667014

The expression of glial fibrillary acidic protein in the brain of streptozotocin rat model of sporadic Alzheimer’s disease


Knezović, Ana; Knapić, Marina; Šimić, Goran; Šalković-Petrišić, Melita
The expression of glial fibrillary acidic protein in the brain of streptozotocin rat model of sporadic Alzheimer’s disease // Clinical Neuropathology 31(4) / Ironside, James (ur.).
Edinburgh: British Neuropathological Society, 2012. str. 290-290 (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
The expression of glial fibrillary acidic protein in the brain of streptozotocin rat model of sporadic Alzheimer’s disease

Autori
Knezović, Ana ; Knapić, Marina ; Šimić, Goran ; Šalković-Petrišić, Melita

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Clinical Neuropathology 31(4) / Ironside, James - Edinburgh : British Neuropathological Society, 2012, 290-290

Skup
10th European Congress of Neuropathology

Mjesto i datum
Edinburgh, Škotska, 06-09.06.2012

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Astrocyte; streptozotocin; Alzheimer's disease

Sažetak
Introduction: Central administration of streptozotocin (STZ-icv) induces Alzheimer-like behavioural and neurochemical changes in rat due to the STZ-icv rat has been recently proposed as its animal model. Activated microglia and astrocytes were found in the cortex and hippocampus up to 8 weeks after the STZ-icv administration. We have investigated the STZ-icv dose-dependency of astrogliosis development 1 week and 3 months after the STZ-icv treatment. Methods: Adult male Wistar rats were administered STZ (0.1, 1 and 3 mg/kg dose) or vehicle (controls) icv injections and sacrificed 1 week and 3 months afterwards. Paraffin-embedded brain sections of pre-mortally fixative perfused animals were analysed by immunohistochemistry of glial fibrillary acidic protein (GFAP), a marker of astrogliosis. Results: Highly increased GFAP expression both in number and cell size was found focused in the cortex, around the cannula penetration area, and in hippocampus 1 week after the STZ-icv administration with all STZ-icv doses as well in the control animals. Three months after the treatment, distribution and cell size were found normalized in all treated groups as well as their number, with the exception of slightly increase with the 0.3 mg/kg STZ-icv dose only. Conclusions: Preliminary results demonstrate that STZ-icv rat model develops acute, non-specific anti-inflammatory response, regardless the STZ-icv dose, which tends to normalize three months after the treatment. Acknowledgement: Supported by the Unity Through Knowledge Fund (UKF 64-10) and MZOS.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
108-1080003-0020 - Mozak, eksperimentalni i cerebralni dijabetes i kognitivni i drugi poremećaji (Melita Šalković-Petrišić, )

Ustanove
Medicinski fakultet, Zagreb